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ABSTRACT 
Background: Both statins and PCSK9 inhibitors lower blood low-density lipoprotein cholesterol 
(LDL-C) levels to reduce risk of cardiovascular events. To assess potential differences between 
metabolic effects of these two lipid-lowering therapies, we performed detailed lipid and metabolite 
profiling of a large randomized statin trial and compared the results with the effects of genetic 
inhibition of PCSK9, acting as a naturally occurring trial. 
Methods: 228 circulating metabolic measures were quantified by nuclear magnetic resonance 
spectroscopy, including lipoprotein subclass concentrations and their lipid composition, fatty acids, 
and amino acids, for 5,359 individuals (2,659 on treatment) in the PROspective Study of Pravastatin 
in the Elderly at Risk (PROSPER) trial at 6-months post-randomization. The corresponding metabolic 
measures were analyzed in eight population cohorts (N=72,185) using PCSK9 rs11591147 as an 
unconfounded proxy to mimic the therapeutic effects of PCSK9 inhibitors. 
Results: Scaled to an equivalent lowering of LDL-C, the effects of genetic inhibition of PCSK9 on 228 
metabolic markers were generally consistent with those of statin therapy (R2=0.88). Alterations in 
lipoprotein lipid composition and fatty acid distribution were similar. However, discrepancies were 
observed for very-low-density lipoprotein (VLDL) lipid measures. For instance, genetic inhibition of 
PCSK9 had weaker effects on lowering of VLDL-cholesterol compared with statin therapy (54% vs. 
77% reduction, relative to the lowering effect on LDL-C; P=2x10-7 for heterogeneity). Genetic 
inhibition of PCSK9 showed no significant effects on amino acids, ketones, or a marker of 
inflammation (GlycA) whereas statin treatment weakly lowered GlycA levels. 
Conclusions: Genetic inhibition of PCSK9 had similar metabolic effects to statin therapy on detailed 
lipid and metabolite profiles. However, PCSK9 inhibitors are predicted to have weaker effects on 
VLDL lipids compared with statins for an equivalent lowering of LDL-C, which potentially translate 
into smaller reductions in cardiovascular disease risk. 
Keywords: metabolic profiling — cholesterol lowering — Mendelian randomization — lipoproteins 
— drug development 
3 (36) 
 
CLINICAL PERSPECTIVE 
1) What is new?  
• Detailed lipoprotein lipid and metabolic effects of statin therapy in a large 
randomized controlled trial are compared with the corresponding effects of 
PCSK9 genetic inhibition in large population studies, acting as a naturally 
occurring trial of PCSK9 inhibitors. 
• We demonstrate generally consistent effects of statins and PCSK9 genetic 
inhibition on a wide range of lipid-related metabolic markers when scaled to a 
similar lowering of LDL-C. 
• Differences are observed in lowering of VLDL lipids and, more subtly, for the 
inflammation marker GlycA, with PCSK9 inhibition appearing to have a weaker 
effect as compared to statins. 
 
2) What are the clinical implications?  
• If VLDL lipids have independent causal effects on cardiovascular disease risk, the 
observed discrepancy on VLDL lipid lowering could contribute to differences in 
cardiovascular risk reductions between statins and PCSK9 inhibitors for an 
equivalent reduction in LDL-C. 
• The null associations on glycolysis related measures and amino acids suggests 
that alternative mechanisms account for the association of genetic variants in 
PCSK9 and risk of type 2 diabetes. 
• These results exemplify the utility of large-scale metabolomic profiling with 
genetics and randomized trial data to uncover potential molecular differences 
between related therapeutics. 
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INTRODUCTION 
Statins are first line therapy to lower blood levels of low-density lipoprotein cholesterol (LDL-C) and 
reduce the risk of cardiovascular events (1-3). Treatment with proprotein convertase subtilisin/kexin 
type 9 (PCSK9) inhibitors has emerged as an additional effective therapy to lower LDL-C, resulting in 
reductions of approximately 45–60% (4,5). Large cardiovascular outcome trials have recently 
demonstrated that PCSK9 inhibitors reduce the risk of major cardiovascular events when added to 
statin treatment (6,7). Based on the first major outcome trials (6), there has been some suggestions 
that PCSK9 inhibitors may be slightly less efficacious than statins for equivalent LDL-C reductions; 
however, other reports suggest that this is not the case, with apparent differences in cardiovascular 
event reduction explained by the short duration of the PCSK9 trials (8). Assessment of the detailed 
lipoprotein and other metabolic effects of statins and PCSK9 inhibitors could provide a more detailed 
understanding of these lipid-lowering therapies and shed light on potential differential effects on 
lipid metabolism. 
The anticipated pharmacological effects of PCSK9 inhibitors may be assessed by LDL-C lowering 
alleles in the PCSK9 gene, which act as unconfounded proxies for the lifetime effects of treatments 
(9-11). The observation of a prominent lower risk of coronary heart disease with LDL-C lowering 
alleles in PCSK9 was pivotal for accelerating the development of anti-PCSK9 therapeutics (10). 
Supporting the validity of using genetic proxies for molecular characterization of lipid-lowering 
targets, we have previously shown that LDL-C lowering alleles in HMGCR (the gene encoding the 
target for statins) closely recapitulate the detailed metabolic changes associated with starting statin 
therapy in longitudinal cohorts, as assessed by nuclear magnetic resonance (NMR) metabolomics 
(12). These detailed metabolic effects of statins were recently confirmed in PREVEND IT (Prevention 
of Renal and Vascular End-stage Disease Intervention Trial), a small randomized trial (13). Other 
studies have assessed the associations of PCSK9 variants with lipoprotein subclass profiles (14,15), 
and the treatment effects of PCSK9 inhibitors on lipoprotein particle concentrations and lipidomic 
measures have been examined in several small trials (16-18). However, prior studies have had 
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limited power to assess potential differences between PCSK9 inhibition and statin therapy for 
equivalent reductions in LDL-C, complicating direct comparisons of their impact on detailed lipid and 
metabolite measures.  
In the present study, we examined the effects of statin therapy and genetic inhibition of PCSK9 on a 
circulating profile of 228 metabolic measures, quantified by NMR metabolomics, including 
lipoprotein subclasses, their lipid concentrations and composition, fatty acid balance, and several 
non-lipid pathways. The metabolic effects of statin treatment were assessed in a large randomized 
placebo-controlled trial. In the absence of NMR metabolomics data from a large randomized trial of 
PCSK9 inhibitor therapy, the anticipated pharmacological effects were examined for a loss-of-
function variant in the PCSK9 gene (10,19). Comparing the metabolomic effects of genetic inhibition 
of PCSK9 to statin therapy provides an opportunity to examine possible discrepancies in many 
circulating biomarkers, and in turn elucidate potential therapeutic differences in the molecular 
mechanisms to reduce cardiovascular risk. 
METHODS 
The authors declare that the summary statistics are available within the article and its online 
supplementary files. The individual patient data analyzed in this study are available by application to 
the respective cohort committees. 
Study design 
An overview of the study design is shown in Figure 1. NMR metabolomics was performed on 5,359 
blood samples from the PROSPER (PROspective Study of Pravastatin in the Elderly at Risk) trial (20) 
at 6-month post-randomization, and 72,185 samples from eight population cohorts from the United 
Kingdom (INTERVAL (21), Avon Longitudinal Study of Parents (ALSPAC) mothers and offspring 
(22,23)), Finland (FINRISK-1997, FINRISK-2007, and Northern Finland Birth Cohort studies 1966 and 
1986 (24-26)), and China (China Kadoorie Biobank (27)). All study participants provided written 
informed consent, and study protocols were approved by the local ethics committees. 
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PROSPER is a double-blind, randomized placebo-controlled trial investigating the benefit of 
pravastatin (40 mg/day) in elderly individuals at risk of cardiovascular disease, with 5,804 
participants (70–82 years old) from Scotland, Ireland and the Netherlands enrolled between 
December 1997 and May 1999 (28). All participants had above average plasma total cholesterol 
concentration (4.0 to 9.0 mmol/L) at baseline and 50% had prior vascular disease. For the present 
study, 5,359 samples (2,659 on pravastatin) were measured by NMR metabolomics; all were 
previously unthawed 6-month post-randomization EDTA plasma samples stored at -80°C (28). 
Metabolite data from baseline samples were not available, however the randomization should 
ensure that there are limited between-group differences at baseline. Replication of the metabolic 
effects of pravastatin in PROSPER was done by comparison with recent results from PREVEND-IT 
(13). 
The metabolic effects of PCSK9 inhibition were assessed via the principle of Mendelian 
randomization using rs11591147-T (R46L), a loss-of-function allele robustly associated with lower 
LDL-C and decreased cardiovascular risk (10,11). The frequency of carriers of this effect allele was 
2.2% (N=3,135 carriers); clinical characteristics of these individuals are specified in Table S1. 
Additional genetic variants in the PCSK9 locus, which have previously been used in Mendelian 
randomization studies on PCSK9 (11,29), and display low linkage disequilibrium with rs11591147 
(R2<0.2), were assessed in sensitivity analyses. To complement the comparison of PCSK9 
rs11591147-T effects against the statin trial, we further examined the metabolic effects of rs12916-T 
in HMGCR in the same study population, acting as a ‘pseudo-trial’ of a very small statin dose by 
naturally occurring randomization of HMG-CoA reductase inhibition (12,30). Among SNPs in HMGCR, 
rs12916 exhibits the strongest association with LDL-C and has been shown to affect hepatic HMGCR 
expression as well as cardiovascular risk (11,12,30). Finally, to corroborate the validity of using 
genetic proxies to mimic the randomized trial effects, we compared metabolic effects of statin 
treatment in PROSPER with the corresponding effects of HMGCR rs12916-T. Pregnant women and 
individuals on lipid-lowering treatment were excluded from the analyses where information was 
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available. Details of the cohorts are provided in Supplementary Methods and Supplementary Table 
1. 
Lipid and metabolite quantification  
High-throughput NMR metabolomics was used to quantify 228 lipoprotein lipids and polar 
metabolite measures from serum or plasma samples in the PROSPER trial and eight cohorts by the 
Nightingale platform (Nightingale Health Ltd, Helsinki, Finland). This provides simultaneous 
quantification of routine lipids, particle concentration and lipid composition of 14 lipoprotein 
subclasses, abundant fatty acids, amino acids, ketones and glycolysis related metabolites in absolute 
concentration units (Supplementary Table 2) (31). The Nightingale NMR metabolomics platform has 
been widely used in epidemiological studies (12,32,33) and the measurement method has been 
previously described (31-35). 
Statistical analyses 
The effects of statin therapy on the 228 metabolic measures in the PROSPER trial were assessed by 
comparing the mean metabolite concentrations in the treatment group with the placebo group at 6 
months after randomization. The between-group difference in concentrations for each metabolic 
measure was quantified separately using linear regression with metabolite concentration as 
outcome and treatment status as predictor, adjusted for age and sex. All metabolite concentrations 
were scaled to standard deviation (SD) units prior to assessing the differences, to enable comparison 
of measures with different units and across wide ranges of concentration levels. Results in absolute 
units are presented in Supplementary Table 3. The percentage differences in metabolite 
concentrations, relative to the placebo group, were examined as secondary analyses. 
The effect of genetic inhibition of PCSK9 on each of the 228 metabolic measures was analyzed 
separately by fitting linear regression models with metabolite concentrations as outcome and 
rs11591147-T allele count as predictor, representing the number of LDL-C lowering alleles. For 
sensitivity analysis, we conducted equivalent tests of each metabolic measure with rs12916-T in 
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HMGCR as the predictor. All genetic analyses assumed an additive effect and were adjusted for age, 
sex, and the first four genomic principal components. Effect sizes and standard errors from each 
cohort were combined using inverse variance-weighted fixed effect meta-analysis. All effect sizes 
were scaled to SD units of metabolite concentrations, as for analyses of PROSPER. The similarity 
between the overall patterns of metabolic effects due to PCSK9 inhibition and statin therapy was 
summarized using the linear fit of the effect estimates of 153 metabolic measures (12), covering all 
assayed measures except lipoprotein lipid ratios and five polar metabolites that could not be reliably 
quantified in PROSPER. 
To facilitate comparison between the substantial metabolic effects of statin therapy with the smaller 
effects from genetic inhibition of PCSK9, results are presented relative to an equivalent (1-SD) 
lowering of LDL-C within each study design (as quantified by NMR metabolomics) (12,35). For the 
statin trial, the estimates derived from comparing statin treatment to placebo were divided by 1.19 
(since statins lowered LDL-C by 1.19 SD); for PCSK9 genetic associations, per-allele effect estimates 
were divided by 0.44; for sensitivity analyses using rs12916 in HMGCR, per-allele effect estimates 
were divided by 0.078. The scaling relative to LDL-C was used to interpret the reported effect sizes as 
a change in concentration in each metabolic measure (in SD units) that accompanies a 1-SD lowering 
of LDL-C by statin therapy and genetic inhibition of PCSK9. This scaling is in line with the principles of 
Mendelian randomization assuming that the genetic variants in PCSK9 and HMGCR serve as 
instruments for the LDL-C exposure. 
Although 228 metabolic measures in total were examined, the number of independent tests 
performed is lower due to the correlated nature of the measures (35). The number of independent 
tests was estimated by taking the number of principal components explaining 99% of the variation in 
the metabolic measures (36). Thus, significance was considered at P<0.0003 to account for the 
testing of 54 independent metabolic measures and three sets of analyses conducted (main effects of 
statins, PCSK9, and differences in their effects). The significance of differences in the effect estimates 
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was determined using the formula below and the corresponding p-values were derived from the 
normal distribution: 
𝑍𝑑𝑖𝑓𝑓 = (𝑏𝑒𝑡𝑎𝑠𝑡𝑎𝑡𝑖𝑛 − 𝑏𝑒𝑡𝑎𝑃𝐶𝑆𝐾9) √(𝑠𝑒𝑠𝑡𝑎𝑡𝑖𝑛
2 − 𝑠𝑒𝑃𝐶𝑆𝐾9
2 )⁄  
To facilitate visualization of the results, we focused on 148 measures that cover all the metabolic 
pathways assayed; results for the remaining measures are shown in Supplementary Figure 1 and 
Supplementary Tables 4-6. Statistical analyses were conducted using R3.2 (www.r-project.org). 
RESULTS 
Figure 1 provides an overview of the study design. Characteristics of the study populations are 
shown in Table 1. Characteristics of each of the eight cohorts used for the genetic analyses 
(N=72,185) are provided separately in Supplementary Table 1. The metabolic effects of statin 
treatment in PROSPER (pravastatin 40 mg/daily) and genetic inhibition of PCSK9 are compared in 
Figure 2. Overall, there was a high concordance of association of statin treatment and genetic 
inhibition of PCSK9 across the detailed metabolic profile (R2=0.88). Nonetheless, some discrepancies 
in effect sizes between statin treatment and PCSK9 rs11591147 were evident, primarily for very-low-
density lipoprotein (VLDL) lipids. 
Effects on lipoprotein lipids 
The specific effects of statin therapy and genetic inhibition of PCSK9 on lipid fractions and 14 
lipoprotein subclasses are shown in Figure 3. Scaled to the same lowering of LDL-C, PCSK9 
rs11591147 displayed similar effects as statin therapy for total cholesterol and intermediate-density 
lipoprotein (IDL)-cholesterol, with no effect on high-density lipoprotein (HDL)-cholesterol. However, 
PCSK9 rs11591147 had a weaker effect on lowering VLDL-cholesterol compared with statins (54% vs. 
77%, relative to the lowering effect on LDL-C (%LDL-C); Phet=2x10-7). These results were substantiated 
by the pattern of reduction in lipoprotein subclass particles: while the effects were similar for 
lowering particle concentrations in all three (small, medium and large) LDL subclasses, the extent of 
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lowering of small, medium-sized and large VLDL particle concentrations was smaller for PCSK9 
rs11591147 compared with statin therapy. A similar discrepancy was observed for cholesterol 
concentrations within the six VLDL subclasses (Figure 4). 
Both for statin therapy and genetic inhibition of PCSK9, the effects on triglyceride measures were 
modest compared to those observed for cholesterol levels in the same lipoprotein subfractions 
(Figure 3). The most pronounced lowering of triglycerides was seen for IDL and LDL particles. For the 
equivalent reductions in LDL-C, PCSK9 rs11591147 displayed a weaker effect than statin therapy on 
lowering total plasma triglycerides (16%LDL-C vs. 37%LDL-C; Phet=3x10-6). Similar differences were seen 
for VLDL and HDL triglycerides. Consistent with the observed discrepancies for lowering of medium 
and large VLDL particles, genetic inhibition of PCSK9 resulted in modestly larger VLDL size, whereas 
statin therapy had no effect on this measure. The effects on apolipoprotein concentrations were 
broadly similar, albeit a larger decrease was observed with statins for the ratio of apolipoprotein B 
to A-I. 
Effects on lipoprotein composition 
In addition to affecting the absolute lipid concentrations, both statin therapy and genetic inhibition 
of PCSK9 had prominent effects on the relative abundance of lipid types (free and esterified 
cholesterol, triglycerides, and phospholipids) in differently sized lipoprotein subclasses (Figure 4). 
The most pronounced lipoprotein composition effects were observed within LDL subclasses, with 
substantial lowering in the relative abundance of cholesteryl esters in LDL particles, alongside 
increases in the abundance of free cholesterol and phospholipids. These effects were very similar for 
statin treatment compared with PCSK9 rs11591147 for the equivalent reductions in LDL-C. Subtle 
discrepancies between statin and genetic inhibition of PCSK9 were observed, e.g., for the extent of 
lowering the fraction of free cholesterol in VLDL particles. The relative fraction of triglycerides in LDL 
and other apolipoprotein-B carrying particles increased similarly for both statins and PCSK9 
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rs11591147, whereas statin therapy caused larger decreases in the relative abundance of 
triglycerides within HDL.  
Effects on fatty acids and polar metabolites 
The effects of statin therapy and genetic inhibition of PCSK9 on fatty acid concentrations and the 
balance of fatty acid ratios are shown in Figure 5. Absolute concentrations of all fatty acids were 
lowered, with the most pronounced lowering for concentrations of linoleic acid, an omega-6 fatty 
acid commonly bound to cholesteryl esters in LDL particles. For the same lowering of LDL-C, the 
effects of statins and PCSK9 rs11591147 were broadly similar, albeit with the lowering of total fatty 
acids being stronger in the case of statins (67%LDL-C vs. 50%LDL-C; Phet=2x10-4). The effects on the fatty 
acid ratios were generally modest, both for statin therapy and PCSK9 rs11591147. A pronounced 
discrepancy between these was observed for the overall degree of fatty acid unsaturation (16%LDL-C 
reduction for PCSK9 vs. 26%LDL-C increase for statin; Phet=4x10-20). 
We further assessed the effects of statin therapy and PCSK9 rs11591147 on polar metabolites and 
other metabolic measures quantified simultaneously in the metabolomics assay, including circulating 
amino acids, glycolysis metabolites, ketone bodies, and GlycA, a marker of chronic inflammation (37) 
(Figure 6). Statin therapy caused only minor effects on these metabolic measures; the strongest 
lowering effects were observed for GlycA (17%LDL-C) and isoleucine (7%LDL-C). The effects of PCSK9 
rs11591147 were also very close to null for these measures, including for glycolysis related 
metabolites and markers of insulin resistance. Of note, information on glucose, lactate, and pyruvate 
were not available in the PROSPER trial due to glycolysis progression after sample collection. 
Comparison to PREVEND-IT trial and Mendelian randomization  
To replicate the detailed metabolic effects of statins observed in PROSPER, we compared them with 
recent results from the PREVEND-IT trial obtained using the same NMR metabolomics platform (13). 
PREVEND-IT also examined the effects of pravastatin (40mg/day) with metabolomic changes 
assessed from baseline to 3-month for 195 individuals on treatment. The detailed metabolic effects 
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of statin treatment were highly concordant between PROSPER and PREVEND-IT (R2=0.96; 
Supplementary Figure 2). When results were scaled to an equivalent lowering in LDL-C, 40 out of 44 
significant discrepancies observed between effects of PCSK9 rs11591147 compared to PROSPER 
were similar or somewhat larger in PREVEND-IT, including the deviations in VLDL lipids; the only 
exceptions were four measures of lipoprotein composition (fraction of free cholesterol in XXL-VLDL, 
triglyceride fraction in XL-VLDL, triglyceride fraction in L-HDL, and phospholipid fraction in S-LDL; 
Supplementary Figure 1).  
We further compared the metabolic effects of PCSK9 rs11591147 to those caused by rs12916 in the 
HMGCR gene, hereby using the genetic variants to effectively act as two naturally occurring trials in 
the same study population. The overall pattern of metabolic effects was highly similar for PCSK9 
rs11591147 and HMGCR rs12916 (R2=0.92; Supplementary Figure 3A). Nonetheless, scaled to the 
equivalent LDL-C reductions, similar deviations were observed for VLDL lipids as when comparing 
PCSK9 rs11591147 to the statin trial results (Supplementary Figure 4). Specifically, the lowering 
effect of HMGCR rs12916-T on particle concentrations of all VLDL subclasses was more similar to the 
effects of statin treatment than to those of PCSK9 rs11591147-T, except in the case of very small 
VLDL. Differences were also observed for cholesterol and triglyceride concentrations in VLDL 
subclasses, whereas the lowering of total and saturated fatty acids was similar for the HMGCR and 
PCSK9 variants. However, power to detect statistical differences on individual measures was modest, 
due to the much weaker LDL-C lowering effect of HMGCR rs12916. Finally, the overall pattern of 
metabolic effects of statin therapy in PROSPER was highly concordant to effects of HMGCR rs12916 
(R2=0.95; Supplementary Figure 3B), signifying pharmacological and genetic inhibition of HMG-CoA 
reductase, respectively.  
In sensitivity analyses, the pattern of metabolic effects from PCSK9 rs11591147 was consistent 
across the cohorts (Supplementary Figure 5). We also observed similar detailed patterns of 
metabolic effects as for rs11591147 when examining other genetic variants in PCSK9 that have 
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previously been used in Mendelian randomization studies (11,29) (Supplementary Figure 6). Results 
for all the 228 metabolic measures quantified are illustrated in Supplementary Figures 1 and 4. 
Metabolic effects in absolute concentration units are listed in Supplementary Table 3. The 
percentage differences in lipid and metabolite concentrations in the PROSPER statin trial are shown 
in Supplementary Figure 7. Effect estimates for all analyses are tabulated in Supplementary Tables 
4–6. 
DISCUSSION 
This study elucidates the comprehensive metabolic effects associated with statin therapy and PCSK9 
inhibition. The results demonstrate that, as compared to statin therapy, genetic inhibition of PCSK9 
yields comparable changes across many different markers of lipid metabolism when scaled to the 
equivalent lowering of LDL-C. However, our results also suggest that PCSK9 inhibitors may be 
somewhat less efficacious at lowering VLDL particles. This could potentially contribute to subtle 
differences in potency for lowering cardiovascular disease for the equivalent reductions in LDL-C (6), 
since recent evidence suggests that VLDL-cholesterol and other triglyceride-rich lipoprotein 
measures may causally contribute to the development of coronary heart disease independent of 
LDL-C (38-40). Moreover, trial data suggest that VLDL-cholesterol is a stronger predictor of 
cardiovascular event risk than LDL-C among patients on statin therapy (41,42). 
Statins and PCSK9 inhibitors both lower circulating LDL-C levels via upregulation of LDL receptors on 
cell surfaces. Consistent with this shared mechanism for clearance of LDL particles, we found that 
statins and genetic inhibition of PCSK9 caused a highly consistent pattern of change across the 
detailed metabolic profile. The metabolomic profiling of the PROSPER trial corroborates previous 
studies with detailed measurements of metabolic effects of statin therapy, both as assessed in 
longitudinal cohorts and in a small randomized trial (12,13). By profiling a large number of 
individuals from multiple cohorts, our results also validate and extend previous studies examining 
the detailed metabolic effects of PCSK9 rs11591147 (14,15). Importantly, in relation to assessment 
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of potential side-effects of PCSK9 inhibition, we did not observe effects on amino acids or other non-
lipid metabolites, many of which are associated with risk of incident diabetes and cardiovascular 
events (32,43,44). Our results on the pattern of lowering VLDL particles due to genetic inhibition of 
PCSK9 are consistent with two small trials assessing the effects of the PCSK9 inhibitors alirocumab 
and evolocumab on lipoprotein particle concentrations; both trials showed substantial reductions in 
small and medium-sized VLDL particles, while the particle concentration of the large VLDL fraction 
was not affected (16,17). Similar results were also found in a small PCSK9-inhibitor trial using 
separation of VLDL subfractions and other lipid measures by ultracentrifugation, which also 
corroborate our results on a stronger effect on lowering of VLDL-cholesterol as compared to total 
plasma triglycerides (18). However, differences in assay methods complicate direct comparison of 
these trials to our results. Overall, these results provide orthogonal evidence for diverse lipoprotein 
lipid alterations by PCSK9 inhibitors, coherent with the comprehensive metabolic effects of statins. 
Currently licensed PCSK9 inhibitors are given either instead of statins – when there is strong 
evidence of statin intolerance in those with familial hypercholesterolemia – or in addition to 
maximally tolerated statins in patients with existing vascular disease (45). Such treatment with 
PCSK9 inhibitors has been shown to be more efficacious in lowering LDL-C than the most potent 
statins (4-6,8). Mendelian randomization studies comparing PCSK9 and HMGCR gene scores on 
cardiovascular outcomes have indicated nearly identical protective effects for equivalent reductions 
in LDL-C (11,46). However, when scaling the metabolic effects to an equivalent lowering in LDL-C, the 
results of the present study indicate subtle differences on multiple lipoprotein lipid measures. The 
most notable discrepancy was for VLDL lipids, suggesting weaker potency of PCSK9 inhibitors in 
clearance of these triglyceride-rich lipoproteins as compared with statins. These findings are 
supported by a recent study providing evidence that statins, but not PCSK9 inhibitors, improve 
triglyceride-rich lipoprotein metabolism after an oral fat load in normolipidemic men (47). The causal 
consequences of these differences in medium-sized and large VLDL particles, that are rich in 
triglycerides, remain unclear and warrant further investigation; whereas IDL and the smallest VLDL 
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particles can penetrate the arterial wall to cause atherosclerosis, it is commonly perceived not be to 
the case for larger VLDL particles (38,48). We also observed a difference in lowering of VLDL-
cholesterol levels; the cholesterol concentrations of VLDL particles are strongly associated with risk 
of myocardial infarction (44) and some studies have suggested that VLDL-cholesterol could underpin 
the link between triglycerides and cardiovascular risk (38,41). If these VLDL particles do play a causal 
role in vascular disease, the discrepancy between statin therapy and PCSK9 inhibition could translate 
into slightly more potent cardiovascular risk reduction for the same LDL-C lowering for statins as 
compared with PCSK9 inhibition. We acknowledge that the present comparison of detailed 
metabolic effects of statin therapy and PCSK9 inhibition does not directly inform on the 
cardiovascular benefits of anti-PCSK9 therapies above current optimal care, but potentially in 
keeping with our findings, the cardiovascular outcome trials on PCSK9 inhibition have demonstrated 
slightly weaker cardiovascular event lowering compared to meta-analysis of statin trials per mmol/L 
reduction in LDL-C (6). While potential explanations for this discrepancy include the short trial 
duration and choice of primary end-point, other explanations, such as differences in anti-
inflammatory effects, have also been suggested (11,49). Our results provide an additional hypothesis 
for exploration: the apparent weaker cardioprotective effects of PCSK9 inhibitors compared to 
statins per unit reduction in LDL-C may be due to weaker reductions in VLDL lipid concentrations by 
PCSK9 inhibition. This hypothesis warrants further investigation, including elucidation of the causal 
role of triglyceride-rich VLDL particles in tandem with further examinations of the detailed lipid 
effect of PCSK9 inhibitors. 
Strengths and limitations of our study warrant consideration. The lack of NMR metabolomics data 
for a PCSK9 inhibition trial motivated the use of a loss-of-function variant in PCSK9 as a proxy for the 
anticipated therapeutic effects. The close match in the detailed metabolic effects of statin therapy 
and HMGCR observed in this study substantiates the validity of using genetic variants to mimic lipid-
lowering effects in randomized trial settings. While we note that the metabolic profile of other 
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statins may differ to that of pravastatin, the similarity between HMGCR and statin therapy we 
identified provides reassurances about the generalizability of our findings to other statin types. To 
robustly assess the metabolic effects of genetic inhibition of PCSK9, we had more than five times the 
sample size of prior studies examining PCSK9 rs11591147 on lipoprotein subclass profiles (14,15). 
Despite the large sample size, we had limited power to detect effects on glycolysis-related 
metabolites due to pre-analytical effects causing depletion of glucose levels in the blood samples. 
Notwithstanding the increased risk for type 2 diabetes linked with PCSK9 rs11591147-T, our results 
indicating minute effects on glycolysis traits are in line with larger studies reporting null effects on 
fasting glucose for this SNP. The divergency in VLDL lipid lowering effects between statins and 
genetic inhibition of PCSK9 could potentially be attributable to differences in the clinical 
characteristics of the older, high-risk patients of the PROSPER trial as compared to the younger 
cohort participants included in the genetic analyses. However, similar VLDL lowering effects due to 
pravastatin as observed in here PROSPER were recently reported in PREVEND IT (13) with younger 
and lower-risk trial participants (Figure S1). The differences in VLDL effects were also recapitulated 
when directly comparing the effects of genetic inhibition of PCSK9 to that of HMGCR in the same 
study population (Figure S4), providing reassurance that the observed VLDL differences are primarily 
due to the molecular mechanisms. Furthermore, the scaling of results to the LDL-C lowering 
magnitude enables comparison of the metabolic effects regardless the possible differences in the 
absolute lipid levels between the study populations. A strength of the metabolomics platform used 
is the ability to profile lipoprotein subclasses and their lipid composition at high-throughput, 
however we acknowledge that other assays may provide even deeper characterization of lipid 
metabolism and non-lipid pathways to further clarify the molecular effects of lipid-lowering 
therapies (50). 
 
In conclusion, we found highly similar metabolic effects of statin therapy and genetic inhibition of 
PCSK9 across a comprehensive profile of lipids, lipoprotein subclasses, fatty acids, and polar 
17 (36) 
 
metabolites. The detailed profiling of lipoprotein subclasses revealed weaker effects of PCSK9 
inhibition on VLDL particles and their cholesterol concentrations as compared with statins, when 
scaled to an equivalent lowering of LDL-C. If some of these VLDL lipids have independent causal 
effects on cardiovascular risk, this could contribute to subtle differences in cardiovascular event 
reduction between statins and PCSK9 inhibitors. More broadly, these results exemplify the utility of 
large-scale metabolomics in combination with randomized trials and genetics to uncover potential 
molecular differences between related therapeutics. 
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Table 1. Baseline characteristics of participants in the PROSPER statin trial and cohorts for 
analyses of genetic inhibition of PCSK9. 
Characteristics PROSPER statin trial Cohorts in analyses of 
genetic variants 
Placebo Pravastatin 
Number of individuals 2,700 2,659 72,185 
Male (%) 48.3 48.3 47.1 
Age (year) 75.3 ± 3.4 75.4 ± 3.3 39.3 ± 5.3 
BMI (kg/m2) 26.8 ± 4.3 26.8 ± 4.1 25.2 ± 4.4 
Triglycerides (mmol/L) 1.5 ± 0.7 1.5 ± 0.7 1.2 ± 0.6 
Total cholesterol (mmol/L) 5.7 ± 0.9 5.7 ± 0.9 4.5 ± 1.0 
HDL cholesterol (mmol/L) 1.3 ± 0.3 1.3 ± 0.4 1.4 ± 0.4 
Friedewald LDL cholesterol (mmol/L)  3.8 ± 0.8 3.8 ± 0.8  2.4 ± 0.8 
Values are mean±SD.  
* Pooled results of eight cohorts from different geographical and ethnic backgrounds and age 
distributions; characteristics of each cohort are detailed in Table S1.  
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Figure 2. Consistency of metabolic effects of statin treatment and PCSK9 rs11591147-T. 
The effect size of each metabolic measure is given with 95% confidence intervals in gray vertical and 
horizontal error bars. Color coding for the metabolic measure indicates the P-value for 
heterogeneity between statin therapy and PCSK9 rs11591147-T. R2 = 0.880 indicates goodness of fit 
(correlation squared). The red dashed line denotes the linear fit for the consistency of the metabolic 
effects (slope of this line = 0.879). 
C: cholesterol; FA: fatty acids; HDL: high-density lipoprotein; IDL: intermediate-density lipoprotein; 
LDL: low-density lipoprotein; PL: phospholipids; PUFA: polyunsaturated fatty acids; TG: triglycerides; 
very-low-density lipoprotein. A full list of metabolite names is given in Supplementary Table 2.  
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Figure 3. Effects of statin treatment and genetic inhibition of PCSK9 on lipoprotein and lipid levels. 
Differences in lipoprotein and lipid levels due to statin treatment were assessed in the PROSPER trial 
at 6-month post randomization (black diamonds; n=5359 for which 2659 were on pravastatin 
40mg/day). The corresponding effects of PCSK9 rs11591147-T were assessed for n=72,185 by meta-
analysis of eight cohorts (red circles). Error bars indicate 95% confidence intervals. Effect estimates 
are shown in SD-scaled concentration units (top axis) and relative to the lowering effect on LDL-C 
(bottom axis). The results for different lipid types within the 14 lipoprotein subclasses are shown in 
Supplementary Figure 1. Effects in absolute concentration units are listed in Supplementary Table 3.  
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Figure 4. Effects of statin treatment and genetic inhibition of PCSK9 on lipoprotein composition.  
Differences in lipoprotein composition measures due to statin treatment were assessed 6-months 
post randomization in the PROSPER trial (black). The corresponding effects of PCSK9 rs11591147-T 
were assessed for n=72,185 (red). Error bars indicate 95% confidence intervals. Results are shown in 
SD-scaled concentration units (top axis) and relative to the lowering effect on LDL-C (bottom axis).  
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Figure 5. Effects of statin treatment and genetic inhibition of PCSK9 on fatty acids. 
Differences in fatty acid levels due to statin treatment were assessed 6-months post randomization 
in the PROSPER trial (black). The corresponding effects of PCSK9 rs11591147-T were assessed for 
n=72,185. Error bars indicate 95% confidence intervals. Results are shown in SD-scaled 
concentration units (top axis) and relative to the lowering effect on LDL-C (bottom axis).  
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Figure 6. Effects of statin treatment and genetic inhibition of PCSK9 on polar metabolites. 
Differences in metabolite levels due to statin treatment were assessed 6-month post randomization 
in the PROSPER trial (black). The corresponding effects of PCSK9 rs11591147-T were assessed for 
n=72,185. Error bars indicate 95% confidence intervals. Glycine, glucose, lactate, pyruvate and 
glycerol measures were not available from PROSPER. Results are shown in SD-scaled concentration 
units (top axis) and relative to the lowering effect on LDL-C (bottom axis). 
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